Cardiovascular Systems Added to Russell 2000® Index
June 27 2011 - 8:00AM
Business Wire
Cardiovascular Systems, Inc. (CSI) (Nasdaq:CSII), a medical
device company developing and commercializing innovative
interventional treatment systems for peripheral and coronary artery
disease, has been added to the Russell 2000® Index. The index
measures the performance of the 2,000 largest U.S. companies based
on total market capitalization. The Russell Investment Group
recently reconstituted its indexes, and Russell 2000 membership
went into effect at market close on June 24, 2011, and will remain
in place for one year.
“Inclusion in the latest Russell 2000 Index recognizes CSI’s
growth and enhances our visibility among investors,” said David L.
Martin, CSI president and chief executive officer. “Within the last
year, we launched our third-generation Stealth 360°™ Orbital PAD
System with significant ease-of-use innovations, expanded our
wealth of clinical data demonstrating our orbital technology’s
superior safety and effectiveness in treating peripheral arterial
disease (PAD), and launched our pivotal trial for a coronary
application in calcified lesions. Our progress on these fronts
positions CSI for strong growth in both the PAD and large
underserved coronary markets.”
The Russell 2000 Index is constructed to provide a
comprehensive, unbiased and stable barometer of the broad market
and is completely reconstituted annually to ensure new and growing
equities are reflected.
Safe Harbor
Certain statements in this news release are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and are provided under the protection of the
safe harbor for forward-looking statements provided by that Act.
For example, statements in this press release regarding CSI’s
potential strong growth in both the PAD and coronary markets are
forward-looking statements. These statements involve risks and
uncertainties which could cause results to differ materially from
those projected, including but not limited to CSI’s clinical
trials; the performance of the Diamondback Systems; the FDA process
relating to the coronary application; and other factors detailed
from time to time in CSI’s SEC reports, including its most recent
annual report on Form 10-K and subsequent quarterly reports on Form
10-Q. CSI encourages you to consider all of these risks,
uncertainties and other factors carefully in evaluating the
forward-looking statements contained in this release. As a result
of these matters, changes in facts, assumptions not being realized
or other circumstances, CSI's actual results may differ materially
from the expected results discussed in the forward-looking
statements contained in this release. The forward-looking
statements made in this release are made only as of the date of
this release, and CSI undertakes no obligation to update them to
reflect subsequent events or circumstances.
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a
medical device company focused on developing and commercializing
innovative solutions for treating vascular and coronary disease.
The company’s Stealth 360°™, Diamondback 360® and Diamondback
Predator 360® Orbital PAD Systems treat calcified and fibrotic
plaque in arterial vessels throughout the leg in a few minutes of
treatment time, and address many of the limitations associated with
existing surgical, catheter and pharmacological treatment
alternatives. The U.S. FDA granted 510(k) clearance for the use of
the Diamondback 360° in August 2007 and for the Stealth 360° in
March 2011. To date, more than 46,000 PAD procedures have been
performed using the Diamondback 360° in leading institutions across
the United States.
CSI has also commenced its ORBIT II Investigational Device
Exemption clinical trial to evaluate the safety and effectiveness
of its Diamondback 360° System in treating coronary arteries. The
coronary system is under clinical investigation and is currently
not commercially available in the United States.
For more information, visit the company’s website at
www.csi360.com.
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jul 2023 to Jul 2024